News

Yahoo Finance2y
Corvus Pharmaceuticals to Present Updated CPI-818 (ITK Inhibitor) Data at the 64th American Society of Hematology (ASH) Annual Meeting & Exposition
Nov. 03, 2022 (GLOBE NEWSWIRE) -- Corvus Pharmaceuticals ... the Company’s ITK inhibitor, at the 64 th American Society of Hematology (ASH) Annual Meeting & Exposition, which is taking place ...
Yahoo Finance1y
Corvus Pharmaceuticals to Present New Interim Soquelitinib Data from its Phase 1/1b T Cell Lymphoma Trial at the 65th American Society of Hematology (ASH) Annual Meeting ...
Nov. 02, 2023 (GLOBE NEWSWIRE) -- Corvus Pharmaceuticals ... with relapsed peripheral T cell lymphoma (PTCL), at the 65th American Society of Hematology (ASH) Annual Meeting & Exposition, which ...
Nasdaq5y
Corvus Pharmaceuticals to Present Preclinical and Early Clinical Data from the Phase 1/1b Trial with CPI-818 at the American Society of Hematology (ASH) Annual Meeting
About Corvus Pharmaceuticals Corvus Pharmaceuticals is a clinical-stage biopharmaceutical company focused on the development and commercialization of precisely targeted oncology therapies.
FOX31 Denver2y
Corvus Pharmaceuticals to Present New CPI-818 Data Demonstrating the Potential of ITK Inhibition as a Treatment for Solid Tumors at the American Association for Cancer Research ...
Corvus Pharmaceuticals, Inc. (Nasdaq: CRVS), a clinical-stage biopharmaceutical company, today announced that it will present new data for CPI-818, the Company’s ITK inhibitor, at the American ...
Business Insider4y
Corvus Announces Upcoming CPI-818 Data Presentations at the American Society of Hematology (ASH) Annual Meeting & Exposition
Nov. 30, 2020 (GLOBE NEWSWIRE) -- Corvus Pharmaceuticals ... will be presented at the 62 nd American Society of Hematology (ASH) Annual Meeting & Exposition, which is taking place as an all ...